On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma

Program Overview
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts treating patients with multiple myeloma.

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Discuss patient-related and disease-related factors that impact the selection of therapy for patients with relapsed/refractory MM
Review the rationale for targeting BCMA in patients with MM, as well as current and emerging approaches that target BCMA, including CAR T-cells, bispecific antibodies, and antibody-drug conjugates
Evaluate strategies to manage adverse events that may be encountered with the use of anti-BCMA therapies